Preservation of Venous Valvular Function After PMT for Acute DVT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-06

Study Completion Date

2025-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the venous valvular function after pharmacomechanical thrombectomy (PMT) for acute femoral-popliteal venous thrombosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Clinical Outcomes of the Embolic Protection System in Preventing Distal Embolism During Femoropopliteal Debulking Procedures

NCT07282301

Femoropopliteal Disease

RECRUITING

Proximal TEmporary oCclusion Using Balloon Guide Catheter for Mechanical Thrombectomy

NCT05592054

Acute Ischemic Stroke Large Vessel Occlusion Thrombectomy +1 more

TERMINATED NA

The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.

NCT04861506

Thromboembolic Disease Lower Extremity Problem Endovascular Treatment +2 more

RECRUITING

Angioplasty-stenting vs Optimal Medical Treatment on Post-thrombotic Syndrome Reduction

NCT04250025

Post Thrombotic Syndrome

RECRUITING NA

Contemporary Endovascular Therapies in Treatment of Acute Iliofemoral Deep Vein Thrombosis

NCT03901872

Thrombolysis Deep Vein Thrombosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients presenting with symptoms in the lower extremity due to the femoral venous thrombosis involving or not involving iliac and popliteal veins treated with percutaneously pharmacomechanical catheter-directed thrombolysis via AngioJet devices or anticoagulation alone were included in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Deep Venous Thrombosis of Femoral Vein (Disorder)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pharmacomechanical Catheter-directed Thrombolysis for acute DVT

AngioJet, Boston Scientific

Group Type EXPERIMENTAL

AngioJet device

Intervention Type DEVICE

A device can be used for thrombus aspiration and thrombolysis.

anticoagulation alone for acute DVT

Group Type PLACEBO_COMPARATOR

anticoagulation alone

Intervention Type OTHER

a medicine for anticoagulation therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AngioJet device

A device can be used for thrombus aspiration and thrombolysis.

Intervention Type DEVICE

anticoagulation alone

a medicine for anticoagulation therapy

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zalente rivaroxaban

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with acute symptomatic proximal DVT involving the femoral, and/or popliteal vein, common femoral vein, iliac veins (with or without other involved ipsilateral veins) were enrolled at seven vascular centers in China. Patients were treated with PCDT via Zelante device (Boston Scientific).